One or more embodiments of the present invention are directed to a medical device having a textured surface with an arithmetical mean height value (Sa) below 3.0 μm and a developed interfacial area ratio (Sdr) above 1.0 and a density of peaks (Spd) above 1×10.sup.6 peaks/mm.sup.2; a process of preparing such a medical device using a microstructured template; and a method of treating a mammal with such a medical device.

Provided is an intraocular lens including: an optic portion; and a haptic portion extending from the optic portion, wherein a pattern having ridges and grooves is formed on at least one of the optic portion and the haptic portion, and each of the grooves has a nanostructure roughness. Provided also is a method of manufacturing an intraocular lens, the method including: seating an object to be processed including an optic portion and at least one haptic portion extending from the optic portion, processing a predetermined pattern for guiding cells by performing laser irradiation on the haptic portion and the optic portion, forming grooves having a nanostructure surface roughness in the predetermined pattern formed by laser beams, and the surface of each of the grooves has an average roughness Ra less than 200 nm.

An ophthalmic device is provided for a patient that has a basic prescription for distant vision, the ophthalmic device including a primary optic and a supplemental optic. The primary optic is configured for placement in the eye and has a base optical power configured to substantially provide the basic prescription. The supplemental optic has an optical power that is less than the optical power of the primary optic and is configured to provide, in combination with the primary optic, a combined optical power that provides the basic prescription of the patient. In addition, at least one surface of the primary optic is configured to deform in response to an ocular force so as to modify the combined optical power by at least 1 Diopter. The ophthalmic device may further include a movement assembly operably coupled to the primary optic that is structured to cooperate with the eye to effect accommodating deformation of the primary optic in response to an ocular force produced by the eye. The movement assembly may also be configured to provide accommodating axial movement of the primary optic.

A medical product comprises a biodegradable filament and a non-biodegradeable coating. The biodegradable filament forms a stent body having a first end portion, a middle portion, and a second end portion opposite the first end portion. The middle portion extends between the first and second end portions. The non-biodegradeable coating encapsulates the at least one biodegradable filament along the middle portion of the stent body. The non-biodegradeable coating forms a barrier such that the non-biodegradeable coating prevents degradation of the at least one biodegradable filament along the middle portion. The first and second end portions are uncoated. After implantation, the end portions of the stent may biodegrade. The middle portion will not biodegrade due to its encapsulation by the non-biodegradeable coating.

The present invention relates to the field of implants. In particular, the present invention relates to an implant for tissue reconstruction which comprises a scaffold structure that includes a void system for the generation of prevascularized connective tissue with void spaces for cell and/or tissue transplantation. Moreover, the present invention relates to a method of manufacturing such an implant, to the internal architecture of such an implant, to a removal tool for mechanical removal of space-occupying structures from such an implant, to a kit comprising such an implant and such a removal tool, to a removal device for the removal of superparamagnetic or ferromagnetic space-occupying structures from such an implant, as well as to a guiding device for providing feedback to a surgeon during the procedure of introducing transplantation cells into the void spaces generated upon removal of space-occupying structures from such an implant.

The present invention relates to a method for preparing a surgical anti-adhesion barrier film comprising the following steps: a°) a first solution, comprising an oxidized collagen is prepared, b) a polyphosphate compound is added to the solution of a) in a quantity so as to obtain a concentration of polyphosphate ranging from 0.007 to 0.7%, by weight, with respect to the total weight of the solution, c) the pH of the solution obtained in b) is adjusted to about 9 by addition of a base or to about 5.1 by addition of an acid, d) a diluted solution is prepared by adding water to solution of c), e) a first layer of solution obtained in c) is casted on an inert support, f) before complete gelation of the layer obtained in d), a second layer, of diluted solution obtained in d) is applied on top of said first layer and let to gelify, g) the gelified first and second layers are dried to obtain a film. The invention further relates to a film obtainable by such a method and to a surgical implant comprising a prosthetic fabric and such a film.

The present invention relates to a coating composition for an in-vivo implantable prosthesis including a photoinitiator, a crosslinking agent, and a phosphorylcholine (pc) monomer having an acrylate group, a method of coating an in-vivo implantable prosthesis using the coating composition, and a cosmetic prosthesis coated with the crosslinked polyphosphorylcholine.

An in-vivo implantable prosthesis coated with crosslinked polyphosphorylcholine may be manufactured by a simple method of applying a coating composition including a photoinitiator, a crosslinking agent, and a phosphorylcholine (pc) monomer having an acrylate group according to the present invention, and then irradiating uv rays. The crosslinked polyphosphorylcholine coating may provide hydrophilicity for the surface and may also remarkably reduce adsorption of proteins and fibroblasts, which may cause side effects such as capsular contracture. Further, the coating has strong enough not to peel off even under stimulation, and therefore, it is maintained under vigorous activity after implantation, thereby being usefully applied to the manufacture of an in-vivo implantable prosthesis with reduced side effects, such as breast prosthesis for cosmetic surgery.

A prosthetic heart valve can have one or more hermetic layers. The inner skirt and/or the outer skirt can comprise one or more hermetic layers, or the entire valve frame can be encapsulated within one or more hermetic layers. Each hermetic layer can be substantially nonporous or can have pores therein that are sized to discourage cellular ingrowth. The hermetic layer can prevent ingrowth of surrounding native tissue, thereby reducing pannus formation on the prosthetic leaflets. Alternatively or additionally, shapes of the leaflets of the valvular structure of the prosthetic valve and/or the coupling of the leaflets to the valve frame can be selected to avoid the incidence of stasis when implanted at a relatively low pressure gradient hemodynamic location. Such a prosthetic heart valve may reduce the risk of thrombosis.

Described herein are tissue grafts derived from the placenta that possess good adhesion to biological tissues and are useful in wound healing applications. In one aspect, the tissue graft includes (1) two or more layers of amnion, wherein at least one layer of amnion is cross-linked, (2) two or more layers of chorion, wherein at least one layer of chorion is cross-linked, or (3) one or more layers of amnion and chorion, wherein at least one layer of amnion and/or chorion is cross-linked. In another aspect, the grafts are composed of amnion and chorion cross-linked with one another. In a further aspect, the grafts have one or more layers sandwiched between the amnion and chorion membranes. The amnion and/or the chorion are treated with a cross-linking agent prior to the formation of the graft. The presence of the cross-linking agent present on the graft also enhances adhesion to the biological tissue of interest. Also described herein are methods for making and using the tissue grafts.

The present invention relates to a bio-functionalized fibrous structure with a core/shell architecture for partial or total repair of human tendons or ligaments. The architecture based on a core/shell system grants to the fibrous structure a specific physical and mechanical behaviour when it is repeatedly mechanically loaded, as happens with a native tendon or ligament in constant usage in the human body. The core is based on several sub-components, namely braided structures parallelly assembled, which are enclosed by a braided shell. Additionally, a selective bio-functionalization of the two parts of the core/shell structure can be applied in order to selectively improve or avoid the in vivo cell adhesion.